describe with all images and flowcharts about moisturizers related to unani and modern perspectives acoording to old and recent advancements

Checking Date & Time

Reading File

Finding Sources

Reading File

Finding Sources

Searching PubMed

moisturizer skin barrier emollient humectant

Reading File

Finding Sources

Searching PubMed

moisturizer emollient skin barrier

Reading File

Finding Sources

Searching Images

skin moisturizer mechanism stratum corneum barrier diagram

Reading File

Finding Sources

Searching Images

Unani herbal plant oils skin treatment traditional medicine

Searching the Web

Unani medicine moisturizers murattibal skin care traditional concepts emollients

Searching PubMed

Unani medicine skin aging moisturizer herbal

Searching Images

emollient humectant occlusive moisturizer classification types comparison

Reading File

Loading Image

Searching PubMed

Unani skin aging innate moisture herbal formulation

Reading Article

PMID: 39715571

Reading Article

PMID: 40176773

Reading Article

PMID: 40231699

Moisturizers: Unani & Modern Perspectives — Old Traditions to Recent Advances

PART 1 — UNANI PERSPECTIVE

1.1 Foundational Concepts

Unani medicine (Tibb-e-Unani) is rooted in Greco-Arabic traditions, originating from Hippocrates, systematized by Galen, and perfected by Arab scholars — Avicenna (Ibn Sina), Razi (Zakariya al-Razi), and Al-Zohrawi (Albucasis).

The Unani paradigm of skin health revolves around two primary physiological constants:

Unani Concept	Description
Hararat Ghariziyya (Innate Heat)	Vital thermal energy inherent in all living tissues
Rutubat Ghariziyya (Innate Moisture)	Natural body moisture sustaining tissue suppleness and vitality

Core principle: With aging, both Hararat Ghariziyya and Rutubat Ghariziyya decline progressively from birth. This causes weakening of Tabiyat (nature/vital force), slowing of bodily functions, reduced production of Akhlaat (humors), and excess production of Rutubat Fozliyya (extraneous/waste moisture). The result is a shift toward Mizaj-e-Sawda (melancholic temperament) — dry, cold in quality — manifesting as xerosis, wrinkles, and aged skin. [PMID: 39715571 — Bibi Chand & Husain Safder, 2025]

1.2 Unani Theory of Skin Mizaj (Temperament)

┌─────────────────────────────────────────────────────────────┐
│           UNANI TEMPERAMENT (MIZAJ) OF SKIN                 │
│                                                             │
│   Hot + Moist (Dam / Sanguine) → Well-hydrated, radiant    │
│   Hot + Dry  (Safra / Bilious) → Oily, prone to acne       │
│   Cold + Moist (Balgham / Phlegmatic) → Pale, puffy skin   │
│   Cold + Dry  (Sawda / Melancholic) → Dry, wrinkled skin   │
│                          ↓                                  │
│          Moisture-restoring therapies target:              │
│          Cold + Dry Mizaj (Yabus + Bard)                   │
│          → Murattibal (Moistening) agents used              │
└─────────────────────────────────────────────────────────────┘

1.3 Historical Unani Texts on Skin Cosmetics

Scholar	Era	Contribution
Hippocrates	~460–370 BCE	Foundation of temperament theory; basis of skin health
Dioscorides	40–90 CE	Materia Medica — plant oils for skin
Galen	129–216 CE	Stabilized theory of humors; introduced cold cream (Ceratum Galeni)
Razi (Zakariya al-Razi)	854–925 CE	Chapter "Zeenat wa Araish" (Beautification) in Kitab al-Mansuri
Al-Zohrawi (Albucasis)	936–1013 CE	Kitab al-Tasrif (30 volumes) — cosmetics as Adwiyat al-Zinat (beautifying drugs)
Ibn Sina (Avicenna)	980–1037 CE	Al-Qanun fi'l-Tibb — detailed skin moisture management

1.4 Unani Classification of Skin Moisturizing Agents

Murattibal (Moisteners — agents that add moisture)

These correct dryness (Yuboosat) by increasing Rutubat in tissues:

UNANI MOISTURIZING DRUGS (MURATTIBAL)
│
├── PLANT-BASED (Nabati)
│   ├── Roghan Badam (Almond oil)       — Softens, nourishes, repairs dry skin
│   ├── Roghan Zaitoon (Olive oil)      — Rich emollient; used since antiquity
│   ├── Roghan Kunjad (Sesame oil)      — Warming, penetrating emollient
│   ├── Roghan Narjeel (Coconut oil)    — Occlusive; prevents TEWL
│   ├── Roghan Arandi (Castor oil)      — Thick humectant/occlusive
│   ├── Aloe vera (Sibr)                — Humectant, anti-inflammatory
│   ├── Honey (Asal)                    — Humectant, antimicrobial
│   └── Beeswax (Mom)                   — Occlusive, emulsifier in Unguents
│
├── ANIMAL-BASED (Hayawani)
│   ├── Mum (Beeswax)                   — Occlusive barrier former
│   ├── Fat of various animals          — Historical occlusives
│   └── Milk (Sheer) / Butter (Makhkhan) — Soothing, emollient
│
└── MINERAL-BASED (Madani)
    ├── Multani mitti (Fuller's earth)  — Absorbent cleanser
    └── Kaolin/Clay minerals            — Skin-softening

Mulayyinaat (Emollients — agents that soften skin texture)

Smooth and soften the stratum corneum
Correct Khushunat (roughness)
Examples: Roghan-e-Badam Shirin (sweet almond oil), Roghan-e-Zaitoon

Murakhkhiyat (Relaxants — agents that relax contracted/tense skin)

Relieve tightness and rigidity
Used in conditions like Tashannuj (spasm) or chronically dry skin

1.5 Unani Cosmeceutical Formulations for Skin Moisture

Classical Unani topical preparations included:

Formulation Type	Unani Name	Ingredients	Modern Equivalent
Ointment	Marham	Wax + oil base + botanicals	Ointment/unguent
Paste	Zimaad	Powder + oil/fat	Thick paste
Cream	Naqoo'	Water + oil emulsion	Cream
Oil	Roghan	Fixed vegetable/animal oils	Oil formulation
Poultice	Tila	Applied topically for skin care	Topical application

Key classical formulation — Galenic Cold Cream (ancestor of modern moisturizer):

Beeswax + Rose water + Almond/Olive oil
Galen (129–216 CE) described this as a water-in-oil emulsion — the earliest known moisturizing cream in history

1.6 Unani Management Protocol for Dry Skin (Yuboosat-e-Jild)

ASSESSMENT
    │
    ▼
Identify Mizaj (Temperament) → Cold + Dry (Sawda)?
    │
    ▼
RESTORE INNATE MOISTURE (Rutubat Ghariziyya)
    │
    ├─── Tadbeer (Regimenal Therapy)
    │    ├── Hammam (Steam bath) — hydrates and opens pores
    │    ├── Taleeq (Massage with oils)
    │    └── Appropriate diet (moist, warm foods)
    │
    └─── Ilaj-bil-Dawa (Drug Therapy)
         ├── Internal: Murattibal drugs (almond oil, honey)
         └── External (Tila/Marham): Roghan Badam + Roghan Zaitoon
              + Mum (beeswax) + Rose water

PART 2 — MODERN SCIENTIFIC PERSPECTIVE

2.1 Skin Anatomy Relevant to Moisturization

The outermost layer of skin — the stratum corneum (SC) — is the primary site of moisturization:

Stratum Corneum Water Diffusion Gradient

Stratum corneum showing retained water below and insensible sweat loss (TEWL) above — the basis of all moisturizer action

Key SC structural components:

Corneocytes — "bricks" (protein-rich, flattened dead cells)
Intercellular lipid bilayers — "mortar" (ceramides + cholesterol + free fatty acids in 1:1:1 molar ratio)
Natural Moisturizing Factor (NMF) — hygroscopic compounds derived from filaggrin breakdown (amino acids, pyrrolidone carboxylic acid, urocanic acid, lactate)
Aquaporins — water channel proteins (AQP3 in keratinocytes)

Optimal SC water content: 10–30% by weight — Dermatology 2-Volume Set 5e, pp. 3096–3098

2.2 Transepidermal Water Loss (TEWL)

Infant skin (a) vs. adult skin (b): Infant skin has less organized SC with higher TEWL; adult mature skin retains water more efficiently — but aging reverses this advantage

TEWL is the passive, insensible diffusion of water vapor through skin to the atmosphere. Elevated TEWL = compromised barrier = the primary target of moisturizers.

2.3 Modern Classification of Moisturizers

The Three Functional Classes

┌────────────────────────────────────────────────────────────────┐
│               MODERN MOISTURIZER CLASSIFICATION                │
│                                                                │
│  ┌─────────────┐   ┌────────────────┐   ┌──────────────────┐  │
│  │  OCCLUSIVES │   │   HUMECTANTS   │   │    EMOLLIENTS    │  │
│  │             │   │                │   │                  │  │
│  │ Form oily   │   │ Attract water  │   │ Fill gaps between│  │
│  │ film on SC  │   │ from dermis to │   │ corneocytes;     │  │
│  │ → ↓ TEWL   │   │ SC (& from air │   │ smooth texture   │  │
│  │             │   │ if RH >70%)    │   │                  │  │
│  │ Petrolatum  │   │ Glycerin       │   │ Fatty acids      │  │
│  │ (99% ↓TEWL)│   │ Hyaluronic acid│   │ Fatty alcohols   │  │
│  │ Mineral oil │   │ Urea           │   │ Lanolin          │  │
│  │ Dimethicone │   │ Sodium lactate │   │ Plant oils       │  │
│  │ Beeswax     │   │ Propylene glycol│  │ Ceramides        │  │
│  │ Lanolin     │   │ Sorbitol       │   │ Squalene         │  │
│  │ Castor oil  │   │ Honey          │   │ Silicones        │  │
│  │ Vegetable   │   │ NaPCA          │   │ Cholesterol      │  │
│  │ waxes       │   │ Aloe vera      │   │                  │  │
│  └─────────────┘   └────────────────┘   └──────────────────┘  │
│                                                                │
│    MOST EFFECTIVE COMBINATION = Occlusive + Humectant +       │
│    Emollient working together in one formulation               │
└────────────────────────────────────────────────────────────────┘

Why combination works: Humectants draw water up from the dermis → occlusives trap it at the SC surface → emollients restore texture and lipid integrity. — Dermatology 2-Volume Set 5e, p. 3098

2.4 Mechanism of Action — Step-by-Step Flowchart

DAMAGED / DRY STRATUM CORNEUM
(↓ NMF, ↓ ceramides, ↑ TEWL, tight/rough/flaky skin)
         │
         ▼
APPLY MOISTURIZER
         │
    ┌────┴─────────────────────────┐
    │                              │
    ▼                              ▼
OCCLUSIVE LAYER               HUMECTANT
(e.g. petrolatum)             (e.g. glycerin)
    │                              │
    ▼                              ▼
Fills interstices of SC       Attracts water from
Reduces TEWL by up to 99%     deeper dermal layers
    │                              │
    └──────────┬───────────────────┘
               ▼
    INCREASED SC WATER CONTENT
    (target 10–30% optimal)
               │
    ┌──────────┴──────────────────────┐
    │                                 │
    ▼                                 ▼
EMOLLIENT ACTION              BARRIER REPAIR SIGNAL
(ceramides, fatty acids)      (some TEWL preserved
                               → stimulates lipid synthesis)
    │                                 │
    ▼                                 ▼
Fills gaps between            SC synthesizes new
desquamating corneocytes      intercellular lipids
→ Smooth texture              → Long-term barrier repair
               │
               ▼
    RESTORED SKIN BARRIER
    + IMPROVED HYDRATION
    + SOFT TEXTURE

Based on Dermatology 2-Volume Set 5e, pp. 3708–3733; Fluhr JW et al., Int J Dermatol, 2025 [PMID: 40231699]

2.5 Skin Barrier & the Atopic Dermatitis Paradigm

Skin Barrier Abnormality in Atopic Dermatitis

In atopic dermatitis, filaggrin deficiency reduces NMF → ↑ TEWL → allergen penetration → Th2 immune cascade. Emollients interrupt this cycle by restoring the barrier.

The "outside-in" hypothesis: Barrier failure allows antigen entry → sensitization → inflammation. Moisturizers/emollients break this cycle at the first step. Petrolatum intercalates into the SC and upregulates skin barrier and antimicrobial peptide gene expression. — Fitzpatrick's Dermatology Vol. 1 & 2, p. 406

2.6 Modern Moisturizer Types — Formulation Table

Type	Composition	Best For	Examples
Oil only	Petrolatum	Severely dry/eczematous skin	Vaseline
Oil-in-water emulsion	Water + petrolatum	General dry skin	Eucerin, Vanicream
Polymer-based	Water + polyglyceryl-methacrylate + petrolatum	Sensitive skin	Cetaphil cream
Vegetable oil & wax	Castor oil, corn oil, beeswax, paraffin	Lips, very dry patches	Neutrogena formula
Glycerin-rich	Water + glycerin + petrolatum	Normal to dry skin	Neutrogena hand cream
Ceramide-based	Petrolatum + dimethicone + ceramides	Atopic dermatitis, eczema	CeraVe, EpiCream

Table 153.3 — Dermatology 2-Volume Set 5e

2.7 The Three-Product Skin Care System

SKIN CARE REGIMEN FLOWCHART
         │
         ▼
  1. CLEANSER
  (Remove sebum, bacteria, dead cells)
  ├── True soap (pH 9–10) → best for oily/dirty skin
  ├── Syndet (pH 5.5–7) → best for sensitive/dry skin
  └── Combar (pH 9–10) → best for normal skin
         │
         ▼
  2. ASTRINGENT / TONER (optional)
  (Remove residue; deliver actives)
  ├── Oily skin: salicylic acid, witch hazel
  └── Dry skin: propylene glycol, allantoin
         │
         ▼
  3. MOISTURIZER
  (Repair & maintain epidermal barrier)
  ├── Dry skin → thicker, higher lipid content (cream/ointment)
  ├── Normal skin → lotion or light cream
  └── Oily skin → gel-based, non-comedogenic
         │
         ▼
  OPTIONAL: SUNSCREEN (SPF ≥30, UVA+UVB)
  ├── Zinc oxide (inorganic, well-tolerated)
  └── Titanium dioxide

Dermatology 2-Volume Set 5e, p. 3096; Fitzpatrick's Dermatology

PART 3 — PARALLEL COMPARISON: UNANI vs. MODERN

┌──────────────────────────────────┬──────────────────────────────────┐
│        UNANI CONCEPT             │       MODERN EQUIVALENT          │
├──────────────────────────────────┼──────────────────────────────────┤
│ Rutubat Ghariziyya (innate       │ Natural Moisturizing Factor      │
│ moisture)                        │ (NMF) in stratum corneum         │
├──────────────────────────────────┼──────────────────────────────────┤
│ Murattibal (moistening agents)   │ Humectants + Emollients          │
├──────────────────────────────────┼──────────────────────────────────┤
│ Murakhkhiyat (relaxants)         │ Emollients (texture improvement) │
├──────────────────────────────────┼──────────────────────────────────┤
│ Marham (ointment base)           │ Oil-based / petrolatum ointment  │
├──────────────────────────────────┼──────────────────────────────────┤
│ Mum (beeswax)                    │ Occlusive agent                  │
├──────────────────────────────────┼──────────────────────────────────┤
│ Roghan Zaitoon (olive oil)       │ Squalene, fatty acids, occlusives│
├──────────────────────────────────┼──────────────────────────────────┤
│ Asal (honey)                     │ Humectant (hygroscopic agent)    │
├──────────────────────────────────┼──────────────────────────────────┤
│ Sibr (Aloe vera)                 │ Humectant + anti-inflammatory    │
├──────────────────────────────────┼──────────────────────────────────┤
│ Roghan Badam (almond oil)        │ Emollient (oleic acid rich)      │
├──────────────────────────────────┼──────────────────────────────────┤
│ Galenic cold cream               │ Modern w/o emulsion moisturizer  │
│ (beeswax + rose water + almond   │                                  │
│ oil)                             │                                  │
├──────────────────────────────────┼──────────────────────────────────┤
│ Hammam (steam bath)              │ Wet-wrap / soak-and-smear method │
├──────────────────────────────────┼──────────────────────────────────┤
│ Mizaj-e-Sawda (melancholic =     │ Xerosis / dry skin / eczema      │
│ Cold+Dry temperament)            │ (SC barrier dysfunction)         │
└──────────────────────────────────┴──────────────────────────────────┘

PART 4 — KEY UNANI HERBS WITH MODERN SCIENTIFIC VALIDATION

Unani Drug	Active Constituents	Unani Action	Modern Mechanism
Roghan Badam (Almond oil)	Oleic acid (70%), linoleic acid, Vit E	Murattibal, Mulayyinaat	Emollient; restores SC lipids; antioxidant
Roghan Zaitoon (Olive oil)	Squalene, oleic acid, polyphenols	Murattibal, anti-aging	Emollient + antioxidant; SC lipid replenisher
Asal (Honey)	Fructose, glucose, organic acids	Murattibal	Humectant; osmotic antibacterial; wound healer
Roghan Narjeel (Coconut oil)	Lauric acid (50%), MCTs	Murattibal, Mulayyinaat	Occlusive + antimicrobial (lauric acid)
Sibr (Aloe vera)	Polysaccharides, acemannan	Murattibal, Mubarrid	Humectant; anti-inflammatory; promotes wound healing
Gule Surkh (Rose)	Flavonoids, terpenes, vitamin C	Mubarrid (cooling)	Antioxidant; skin barrier support
Sandal (Sandalwood)	α/β-Santalol	Mubarrid, anti-itch	Anti-inflammatory; soothes reactive skin
Roghan Kunjad (Sesame oil)	Linoleic acid, sesamin	Murattibal	Emollient; UV-absorbing; antifungal
Roghan Arandi (Castor oil)	Ricinoleic acid (90%)	Murattibal, Mulayyin	Thick humectant + occlusive; promotes barrier recovery
Mum (Beeswax)	Esters, hydrocarbons	Marham base	Occlusive; emulsifier; antimicrobial

PART 5 — RECENT ADVANCES (2023–2026)

5.1 Molecular Targets of Modern Moisturizers

Recent clinical evidence shows advanced moisturizers now target specific molecular markers:

Draelos ZD & Nelson DB (2025) [PMID: 40176773] — A new emollient-rich moisturizer demonstrated:

↑ Claudin-4 (CLD4) — tight junction protein; enhances barrier
↑ Aquaporin-3 (AQP3) — water transport into keratinocytes
↑ Hyaluronic Acid Synthase-2 (HAS2) — endogenous HA production
↓ Hyaluronidase-1 (HYAL1) — reduces HA degradation
Clinical result: 116% improvement in skin hydration at 8 weeks

MODERN MOISTURIZER: MOLECULAR MECHANISM
         │
    Applied to SC
         │
    ┌────┴────────────────────────┐
    │                             │
    ▼                             ▼
Barrier proteins upregulated   Water channel support
  (Claudin-4, Filaggrin)        (AQP3 ↑)
         │                             │
         ▼                             ▼
↑ Tight junction integrity     ↑ Transepidermal water delivery
         │                             │
         └──────────┬──────────────────┘
                    ▼
         Hyaluronic acid synthesis ↑ (HAS2)
         Hyaluronidase inhibited (HYAL1 ↓)
                    │
                    ▼
         SUSTAINED ENDOGENOUS HYDRATION
         + STRUCTURAL BARRIER RESTORATION

5.2 Current Standard of Care for Xerosis (2025)

Fluhr JW et al. (2025) [PMID: 40231699] — Restoring Skin Hydration and Barrier Function: Mechanistic Insights Into Basic Emollients for Xerosis Cutis

Key conclusions:

Skin hydration primarily mediated by SC's NMF and intercellular lipid bilayer
Xerosis triggers: Cold weather, aging, pollution, medications, atopic dermatitis, psoriasis, diabetes, hypothyroidism
Standard of care: Basic emollients with humectants (glycerol, urea, lactic acid) + occludents (petrolatum, liquid paraffin)
Basic emollients remain first-line, long-term management for xerosis and associated inflammatory skin diseases

5.3 Ceramide-Centric Formulations

Modern ceramide-containing moisturizers (e.g., CeraVe) directly replenish the SC lipid matrix:

Ceramide 1, 4, 7 — the three key SC ceramide species critical for lamellar bilayer organization
Ceramides + cholesterol + free fatty acids must maintain 1:1:1 molar ratio for optimal barrier function
Deficiency in any → altered bilayer → ↑ TEWL → dry skin / eczema — Dermatology 2-Volume Set 5e, p. 2636

5.4 Microbiome-Aware Moisturizers

Woo YR & Kim HS (2024) [PMID: 38312314] — The skin microbiome interacts critically with the epidermal barrier in aging skin. Next-generation moisturizers are being developed with prebiotics and postbiotics to:

Support Staphylococcus epidermidis (commensal) over S. aureus (pathogen)
Maintain optimal skin pH (5.4) which favors barrier enzyme function

SUMMARY MASTER FLOWCHART

┌──────────────────────────────────────────────────────────────────┐
│              MOISTURIZERS: FROM UNANI TO MODERN SCIENCE          │
│                                                                  │
│  UNANI THEORY               MODERN SCIENCE                       │
│  ─────────────              ────────────────                     │
│  Rutubat Ghariziyya    ──►  Natural Moisturizing Factor (NMF)    │
│  Hararat Ghariziyya   ──►  Metabolic activity of keratinocytes  │
│  Murattibal agents    ──►  Humectants (glycerin, HA, honey)      │
│  Marham (ointment)    ──►  Occlusives (petrolatum, beeswax)      │
│  Mulayyinaat agents   ──►  Emollients (ceramides, fatty acids)   │
│  Hammam (steam bath)  ──►  Wet-wraps / hydration therapy         │
│                                                                  │
│  TRADITIONAL PLANTS → MODERN VALIDATION                          │
│  Roghan Zaitoon → Squalene/oleic acid (emollient)               │
│  Asal (honey) → Humectant + antimicrobial                        │
│  Sibr (aloe) → Polysaccharide humectant + anti-inflammatory     │
│  Mum (beeswax) → Occlusive barrier former                        │
│                                                                  │
│  RECENT ADVANCES (2023–2026)                                      │
│  ► Ceramide-centric formulations (CeraVe)                        │
│  ► AQP3 / Claudin-4 / HAS2 molecular targeting                  │
│  ► Microbiome-aware prebiotics in moisturizers                   │
│  ► Filaggrin-stimulating formulations (AD management)            │
│  ► Bioactive NMF supplements (PCA, urocanic acid, amino acids)   │
└──────────────────────────────────────────────────────────────────┘

Sources

Textbooks:

Dermatology 2-Volume Set 5e — pp. 3096–3098, 3708–3733 (Moisturizers & Skin Care Products)
Fitzpatrick's Dermatology Vol. 1 & 2 — pp. 406, 2636 (Emollients, SC formation, atopic dermatitis)
Pfenninger and Fowler's Procedures for Primary Care — Choosing a Skin Care Regimen

PubMed / Recent Evidence:

Prevention and Management of Skin Aging in Unani System of Medicine — Bibi Chand & Husain Safder, Alt Ther Health Med, 2025 [PMID 39715571]
Emollient-Rich Moisturizer: Three Elements of Natural Moisturization — Draelos ZD & Nelson DB, J Cosmet Dermatol, 2025 [PMID 40176773]
Restoring Skin Hydration — Mechanistic Insights Into Basic Emollients — Fluhr JW et al., Int J Dermatol, 2025 [PMID 40231699]
Microbiota and Skin Barrier in Aging Skin — Woo YR & Kim HS, Front Physiol, 2024 [PMID 38312314]

journal articles different types

Checking Date & Time

Asking for Preferences

Here is a comprehensive breakdown of all types of journal articles, with detailed explanations of each:

Types of Journal Articles — Complete Guide

Overview Flowchart

JOURNAL ARTICLES
│
├── PRIMARY RESEARCH (Original data collected)
│   ├── Experimental
│   │   ├── Randomized Controlled Trial (RCT)
│   │   ├── Non-Randomized / Quasi-Experimental
│   │   └── Laboratory / In Vitro Study
│   └── Observational
│       ├── Cohort Study
│       ├── Case-Control Study
│       └── Cross-Sectional Study
│
├── SECONDARY RESEARCH (Synthesizes existing data)
│   ├── Systematic Review
│   ├── Meta-Analysis
│   └── Narrative Review
│
├── SPECIAL REPORT TYPES
│   ├── Case Report
│   ├── Case Series
│   ├── Technical Report / Short Communication
│   └── Conference Abstract
│
└── OPINION / EXPERT COMMENTARY
    ├── Editorial
    ├── Letter to the Editor
    ├── Commentary
    └── Expert Opinion / Perspective

1. Randomized Controlled Trial (RCT)

Definition: Participants are randomly allocated to an intervention group or control group, then followed for outcomes.

Structure:

Population
    │
    ▼
RANDOMIZATION (random allocation)
    │
    ├──── Intervention Group (receives treatment)
    │            │
    │            ▼
    │      Outcome measured
    │
    └──── Control Group (placebo / standard care)
                 │
                 ▼
           Outcome measured
                 │
                 ▼
         COMPARISON of outcomes

Feature	Detail
Hierarchy	Highest level for evaluating treatment efficacy
Blinding	Single-blind / double-blind / triple-blind
Allocation concealment	Prevents selection bias
CONSORT checklist	Reporting standard
Limitation	Expensive; ethical constraints; may lack real-world generalizability
Example	"Does ceramide moisturizer reduce TEWL vs. petrolatum in atopic dermatitis?"

2. Systematic Review

Definition: A rigorous, pre-defined literature search that identifies, appraises, and synthesizes ALL available evidence on a specific question.

CLINICAL QUESTION (PICO)
    │
    ▼
Comprehensive database search
(PubMed, Cochrane, Embase, CINAHL...)
    │
    ▼
Screening by title/abstract
    │
    ▼
Full-text review
    │
    ▼
Quality appraisal (Cochrane RoB, GRADE)
    │
    ▼
Data extraction
    │
    ▼
SYNTHESIS (Narrative or Quantitative)
    │
    ▼
CONCLUSIONS + GRADE of evidence

Feature	Detail
Hierarchy	Gold standard for evidence synthesis
PRISMA	Reporting standard (Preferred Reporting Items for Systematic Reviews)
Includes	Protocol, search strategy, inclusion/exclusion criteria, risk-of-bias assessment
Limitation	Only as good as included studies; publication bias possible

3. Meta-Analysis

Definition: A statistical method that pools numerical data from multiple studies to produce a single, more powerful estimate of effect.

Study 1 (n=50)  ────┐
Study 2 (n=80)  ────┤
Study 3 (n=120) ────┤──► POOLED STATISTICAL ANALYSIS
Study 4 (n=60)  ────┤         │
Study 5 (n=200) ────┘         ▼
                       FOREST PLOT
                    (Effect sizes + 95% CI)
                              │
                              ▼
                    Combined effect estimate
                    Heterogeneity (I² statistic)
                    Funnel plot for publication bias

Feature	Detail
Output	Forest plot; pooled OR/RR/MD; heterogeneity (I²)
Often combined with	Systematic review
Hierarchy	Highest level of quantitative evidence
Limitation	"Garbage in, garbage out" — poor input studies = poor pooled result

4. Cohort Study

Definition: A group (cohort) with a specific exposure is followed forward in time (prospectively) or traced backward (retrospectively) to observe outcomes.

TIME LINE →→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→

EXPOSED group ──────────────────► Outcome? (Disease / event)
      │ (e.g., uses moisturizer)
      │
      ├──── Outcome YES → Calculate incidence
      └──── Outcome NO

NON-EXPOSED group ───────────────► Outcome? (Disease / event)
      │
      ├──── Outcome YES → Calculate incidence
      └──── Outcome NO

COMPARISON → Relative Risk (RR)

Feature	Detail
Direction	Exposure → Outcome (forward in time)
Best for	Incidence, risk factors, natural history
Measure	Relative Risk (RR)
Limitation	Long follow-up; loss to follow-up; expensive
Example	"Do daily moisturizer users have lower incidence of eczema flares over 2 years?"

5. Case-Control Study

Definition: Starts with outcome (disease/event), then looks backward to compare exposure history between cases (with disease) and controls (without disease).

TIME LINE ←←←←←←←←←←←←←←←←←←←←←

          PRESENT ──────────────► PAST (look back)

CASES (WITH disease/outcome)
      │
      └──► Were they EXPOSED? YES / NO

CONTROLS (WITHOUT disease/outcome)
      │
      └──► Were they EXPOSED? YES / NO

COMPARISON → Odds Ratio (OR)

Feature	Detail
Direction	Outcome → Exposure (backward in time)
Best for	Rare diseases; quick & cheap
Measure	Odds Ratio (OR)
Limitation	Recall bias; selection of controls is tricky
Example	"Were people who developed contact dermatitis more exposed to fragrance moisturizers?"

6. Cross-Sectional Study

Definition: A snapshot in time — exposure and outcome measured simultaneously in a population.

POPULATION
    │
    ▼
SINGLE POINT IN TIME (snapshot)
    │
    ├── Exposed + Disease
    ├── Exposed + No Disease
    ├── Not Exposed + Disease
    └── Not Exposed + No Disease
    │
    ▼
PREVALENCE calculated
ASSOCIATION measured → Prevalence Ratio / OR

Feature	Detail
Direction	No time dimension — simultaneous
Best for	Prevalence, surveys, diagnostic studies
Measure	Prevalence ratio
Limitation	Cannot establish causality (chicken-and-egg problem)
Example	"What proportion of adults with dry skin use moisturizers regularly?"

7. Narrative Review

Definition: A broad, expert-authored synthesis of the literature on a topic — without a formal search protocol.

Feature	Detail
Scope	Broad; expert curated
Search strategy	Not pre-registered or systematic
Best for	Overviews, educational articles, clinical summaries
Limitation	Subject to author bias; not reproducible
Example	"A review of moisturizer mechanisms in atopic dermatitis"

8. Case Report

Definition: A detailed description of one patient's unusual or instructive clinical presentation, diagnosis, and management.

Structure:

Patient Demographics / Background
    │
    ▼
Chief Complaint + History
    │
    ▼
Clinical Examination Findings
    │
    ▼
Investigations (labs, imaging, biopsy)
    │
    ▼
Diagnosis
    │
    ▼
Treatment & Response
    │
    ▼
Follow-up / Outcome
    │
    ▼
DISCUSSION: Why is this case unique? What does it teach?

Feature	Detail
N = 1	Single patient only
Best for	Novel diagnoses, rare reactions, new treatments, teaching lessons
Hierarchy	Lowest level of evidence for causality
Limitation	Cannot generalize; no statistical analysis
Example	"Severe contact allergy to lanolin in a moisturizer — a case report"

9. Case Series

Definition: A collection of multiple patients (typically 3–20) with similar presentation or treatment, described together without a control group.

Feature	Detail
N = multiple	Usually 3–20 patients
Best for	Rare conditions, new procedures, initial safety signals
Hierarchy	Low evidence; no comparison group
Limitation	No controls; selection bias; cannot prove causality
Example	"A series of 10 patients with moisturizer-induced perioral dermatitis"

10. Short Communication / Brief Report

Definition: A condensed original research article presenting preliminary or focused findings, shorter than a full research paper.

Feature	Detail
Length	1500–2500 words, 1–2 tables/figures
Best for	Pilot results, focused observations, quick reports
Review	Peer-reviewed like full articles

11. Editorial

Definition: A short opinion piece written by the journal's editor or an invited expert, commenting on a paper published in the same issue or on a timely topic.

Feature	Detail
Author	Editor-in-chief, section editor, or invited expert
Purpose	Contextualize published research; provide perspective
Evidence level	Very low (opinion)
Not peer-reviewed	Usually invited, not externally reviewed

12. Letter to the Editor

Definition: A brief written response, usually to a recently published article, raising a concern, clarification, reanalysis, or short original observation.

Feature	Detail
Length	150–500 words
Purpose	Critique, correct, or add to a published article
May include	Re-analysis, additional data, rebuttal
Example	Disagreement with the results of an RCT on a specific moisturizer formulation

13. Commentary / Perspective

Definition: A formal, citable expert opinion on a topic, often invited. Longer and more structured than a letter; shorter than a review.

Feature	Detail
Length	800–1500 words
Author	Usually senior expert in field
Purpose	Frame a debate, discuss implications, offer expert standpoint

14. Conference Abstract / Proceedings

Definition: A very short summary of research presented at a scientific conference, published in the conference proceedings.

Feature	Detail
Length	150–300 words
Peer-review	Limited / abstract-only review
Status	Preliminary; may later become a full paper
Limitation	Not fully peer-reviewed; data may change

Evidence Hierarchy Pyramid

         ┌───────────────────────┐
         │   SYSTEMATIC REVIEW   │  ← Highest evidence
         │    + META-ANALYSIS    │
         └──────────┬────────────┘
                    │
         ┌──────────▼────────────┐
         │ RANDOMIZED CONTROLLED │
         │       TRIAL (RCT)     │
         └──────────┬────────────┘
                    │
         ┌──────────▼────────────┐
         │   COHORT STUDY        │
         │  (Prospective/Retro)  │
         └──────────┬────────────┘
                    │
         ┌──────────▼────────────┐
         │  CASE-CONTROL STUDY   │
         └──────────┬────────────┘
                    │
         ┌──────────▼────────────┐
         │  CROSS-SECTIONAL      │
         │       STUDY           │
         └──────────┬────────────┘
                    │
         ┌──────────▼────────────┐
         │  CASE SERIES /        │
         │  CASE REPORT          │
         └──────────┬────────────┘
                    │
         ┌──────────▼────────────┐
         │  EXPERT OPINION /     │
         │  EDITORIAL            │  ← Lowest evidence
         └───────────────────────┘

Comparison Summary Table

Article Type	Study Design	Evidence Level	Key Measure	Best Use
Meta-Analysis	Statistical pooling	⭐⭐⭐⭐⭐	Pooled OR/RR	Definitive effect size
Systematic Review	Synthesis	⭐⭐⭐⭐⭐	Qualitative/Quantitative	Evidence summary
RCT	Experimental	⭐⭐⭐⭐	Risk difference	Treatment efficacy
Cohort	Observational, prospective	⭐⭐⭐	Relative Risk (RR)	Risk factors, prognosis
Case-Control	Observational, retrospective	⭐⭐	Odds Ratio (OR)	Rare diseases
Cross-Sectional	Observational, snapshot	⭐⭐	Prevalence	Prevalence, surveys
Narrative Review	Synthesis (non-systematic)	⭐	Descriptive	Overview, education
Case Series	Descriptive	⭐	Descriptive	Rare conditions
Case Report	Descriptive	⭐	Descriptive	Unique presentations
Editorial	Opinion	—	Opinion	Context, debate
Letter	Opinion/brief data	—	Critique	Response to papers

Key Acronyms You Will Encounter

Acronym	Meaning	Used In
PICO	Population, Intervention, Comparison, Outcome	Systematic reviews, RCTs
CONSORT	Consolidated Standards of Reporting Trials	RCTs
PRISMA	Preferred Reporting Items for Systematic Reviews	Systematic reviews
STROBE	Strengthening the Reporting of Observational Studies	Cohort, case-control, cross-sectional
CARE	CAse REport guidelines	Case reports
GRADE	Grading of Recommendations Assessment	Evidence quality rating
RoB	Risk of Bias	Cochrane tool for RCT quality
NOS	Newcastle-Ottawa Scale	Quality of observational studies
OR	Odds Ratio	Case-control studies
RR	Relative Risk	Cohort studies
HR	Hazard Ratio	Survival/time-to-event analyses
CI	Confidence Interval	All quantitative studies
I²	Heterogeneity statistic	Meta-analyses

This covers the full spectrum of journal article types used across medical, pharmaceutical, and scientific research. If you want examples from any specific type related to moisturizers or Unani medicine, let me know.

make it ppt

Checking Date & Time

Reading File

Running Command

ls -la /home/daytona/workspace/ 2>/dev/null || echo "workspace empty or does not exist"

Running Command

mkdir -p /home/daytona/workspace/journal-articles-ppt && echo "created"

Writing File

~/journal-articles-ppt/make_ppt.js

const pptxgen = require('pptxgenjs');

const pptx = new pptxgen();
pptx.layout = 'LAYOUT_WIDE';
pptx.author = 'Orris';
pptx.company = 'Orris';
pptx.subject = 'Types of Journal Articles';
pptx.title = 'Types of Journal Articles - Detailed Guide';
pptx.lang = 'en-US';
pptx.theme = {
  headFontFace: 'Calibri',
  bodyFontFace: 'Calibri',
  lang: 'en-US'
};

const COLORS = {
  bg: '0B1020',
  card: '121A33',
  accent: '3B82F6',
  accent2: '14B8A6',
  text: 'E6ECFF',
  muted: 'A8B3CF',
  white: 'FFFFFF'
};

function addHeader(slide, title, subtitle='') {
  slide.background = { color: COLORS.bg };
  slide.addShape(pptx.ShapeType.rect, {
    x: 0, y: 0, w: 13.33, h: 0.7,
    fill: { color: '0F1730' },
    line: { color: '0F1730' }
  });
  slide.addText(title, {
    x: 0.45, y: 0.14, w: 9.8, h: 0.35,
    color: COLORS.text, bold: true, fontSize: 20, margin: 0
  });
  if (subtitle) {
    slide.addText(subtitle, {
      x: 0.45, y: 0.5, w: 11.8, h: 0.25,
      color: COLORS.muted, fontSize: 11, margin: 0
    });
  }
}

function addFooter(slide, n) {
  slide.addShape(pptx.ShapeType.line, {
    x: 0.45, y: 7.08, w: 12.4, h: 0,
    line: { color: '233054', pt: 1 }
  });
  slide.addText(`Journal Article Types | Slide ${n}`, {
    x: 0.45, y: 7.14, w: 12.4, h: 0.2,
    color: '7F8DB2', fontSize: 9, align: 'right'
  });
}

function addCard(slide, x, y, w, h, title, body, accent='3B82F6') {
  slide.addShape(pptx.ShapeType.roundRect, {
    x, y, w, h,
    rectRadius: 0.06,
    fill: { color: COLORS.card },
    line: { color: '243357', pt: 1 }
  });
  slide.addShape(pptx.ShapeType.rect, {
    x, y, w: 0.08, h,
    fill: { color: accent }, line: { color: accent }
  });
  slide.addText(title, {
    x: x + 0.18, y: y + 0.1, w: w - 0.24, h: 0.3,
    color: COLORS.white, bold: true, fontSize: 14, margin: 0
  });
  slide.addText(body, {
    x: x + 0.18, y: y + 0.45, w: w - 0.24, h: h - 0.5,
    color: COLORS.text, fontSize: 11, valign: 'top'
  });
}

// Slide 1: Title
{
  const s = pptx.addSlide();
  s.background = { color: COLORS.bg };
  s.addShape(pptx.ShapeType.rect, {
    x: 0.7, y: 1.0, w: 12.0, h: 5.2,
    fill: { color: '111A35' }, line: { color: '243357', pt: 1 }
  });
  s.addText('Types of Journal Articles', {
    x: 1.1, y: 2.0, w: 11.0, h: 0.9,
    color: COLORS.white, bold: true, fontSize: 46, align: 'center'
  });
  s.addText('Detailed Guide with Study Designs, Evidence Hierarchy, and Use Cases', {
    x: 1.1, y: 3.05, w: 11.0, h: 0.45,
    color: COLORS.muted, fontSize: 18, align: 'center'
  });
  s.addShape(pptx.ShapeType.roundRect, {
    x: 4.65, y: 4.15, w: 4.0, h: 0.55,
    fill: { color: COLORS.accent }, line: { color: COLORS.accent }, rectRadius: 0.08
  });
  s.addText('Medical / Scientific Publishing', {
    x: 4.8, y: 4.3, w: 3.7, h: 0.25,
    color: COLORS.white, fontSize: 12, bold: true, align: 'center'
  });
  addFooter(s, 1);
}

// Slide 2: Classification overview
{
  const s = pptx.addSlide();
  addHeader(s, 'High-Level Classification', 'How journal articles are grouped');

  addCard(s, 0.6, 1.0, 4.1, 2.5, 'Primary Research',
`Original data collection\n• Experimental: RCT, quasi-experimental, lab studies\n• Observational: cohort, case-control, cross-sectional\n\nAnswers: What happened in this specific sample?`, COLORS.accent);

  addCard(s, 4.9, 1.0, 4.1, 2.5, 'Secondary Research',
`Synthesis of existing studies\n• Systematic review\n• Meta-analysis\n• Narrative review\n\nAnswers: What is the totality of evidence?`, '14B8A6');

  addCard(s, 9.2, 1.0, 3.5, 2.5, 'Scholarly Discourse',
`Opinion and critique formats\n• Editorial\n• Letter\n• Commentary\n• Perspective`, 'F59E0B');

  addCard(s, 0.6, 3.8, 12.1, 2.8, 'Flow Map',
`Journal Articles\n  ├── Primary Research\n  │    ├── Experimental -> RCT / Non-randomized / Lab\n  │    └── Observational -> Cohort / Case-control / Cross-sectional\n  ├── Secondary Research -> Systematic Review / Meta-analysis / Narrative Review\n  ├── Special Reports -> Case report / Case series / Brief report / Conference abstract\n  └── Opinion -> Editorial / Letter / Commentary`, '8B5CF6');

  addFooter(s, 2);
}

// Slide 3: RCT
{
  const s = pptx.addSlide();
  addHeader(s, 'Randomized Controlled Trial (RCT)', 'Best design to evaluate treatment efficacy');
  addCard(s, 0.6, 1.0, 6.2, 2.3, 'Core Structure',
`Population -> Randomization -> Intervention vs Control -> Outcome comparison\nBlinding: single, double, or triple\nReporting standard: CONSORT`, COLORS.accent);

  addCard(s, 7.0, 1.0, 5.7, 2.3, 'Strengths & Limits',
`Strengths: strong internal validity, lower confounding\nLimits: cost, logistics, ethics, external validity challenges`, '14B8A6');

  addCard(s, 0.6, 3.5, 12.1, 3.0, 'Flowchart',
`Eligible participants\n      ↓\nRandom allocation\n  ↙             ↘\nIntervention   Control (placebo/standard care)\n   ↓               ↓\nOutcome A        Outcome B\n      ↓\nBetween-group effect estimate (RR, ARR, NNT, CI)`, 'F59E0B');
  addFooter(s, 3);
}

// Slide 4: Observational studies
{
  const s = pptx.addSlide();
  addHeader(s, 'Observational Designs', 'Cohort, Case-control, and Cross-sectional');
  addCard(s, 0.6, 1.0, 4.0, 5.8, 'Cohort Study',
`Direction: Exposure -> Outcome\nProspective or retrospective\nMeasure: Relative Risk (RR)\nBest for: incidence, prognosis, risk factors\nLimitation: follow-up burden`, COLORS.accent);

  addCard(s, 4.8, 1.0, 4.0, 5.8, 'Case-Control Study',
`Direction: Outcome -> Exposure (backward)\nMeasure: Odds Ratio (OR)\nBest for: rare diseases\nFast and cost-effective\nLimitations: recall & selection bias`, '14B8A6');

  addCard(s, 9.0, 1.0, 3.7, 5.8, 'Cross-Sectional Study',
`Snapshot at one time point\nExposure and outcome measured together\nBest for: prevalence estimates\nLimitation: cannot establish temporality/causality`, 'F59E0B');
  addFooter(s, 4);
}

// Slide 5: Secondary evidence
{
  const s = pptx.addSlide();
  addHeader(s, 'Systematic Review and Meta-Analysis', 'Highest-level evidence synthesis');
  addCard(s, 0.6, 1.0, 6.2, 2.6, 'Systematic Review',
`Structured question (PICO)\nProtocol-driven search across databases\nScreening + quality appraisal + synthesis\nReporting standard: PRISMA`, COLORS.accent);

  addCard(s, 7.0, 1.0, 5.7, 2.6, 'Meta-analysis',
`Quantitatively pools effect sizes from multiple studies\nOutputs: pooled effect, 95% CI, forest plot, I² heterogeneity\nRisk: garbage-in, garbage-out if source studies are weak`, '14B8A6');

  addCard(s, 0.6, 3.9, 12.1, 2.7, 'Workflow',
`Question -> Search -> Screen -> Full-text eligibility -> Risk-of-bias assessment\n-> Data extraction -> Qualitative synthesis\n-> (Optional) Quantitative pooling (meta-analysis) -> GRADE certainty`, '8B5CF6');
  addFooter(s, 5);
}

// Slide 6: Case report / case series
{
  const s = pptx.addSlide();
  addHeader(s, 'Case Report and Case Series', 'Useful for rare or novel clinical observations');
  addCard(s, 0.6, 1.0, 6.0, 2.7, 'Case Report (N=1)',
`Detailed narrative of one patient\nIncludes: presentation, diagnostics, treatment, outcome\nBest for: rare events, new adverse effects, educational insights\nGuideline: CARE`, COLORS.accent);

  addCard(s, 6.8, 1.0, 5.9, 2.7, 'Case Series (N>1)',
`Multiple similar cases without control group\nDetects early patterns and safety signals\nLimit: descriptive only, no causal inference`, '14B8A6');

  addCard(s, 0.6, 4.0, 12.1, 2.5, 'Typical Case Report Structure',
`Patient profile -> History -> Examination -> Investigations -> Diagnosis\n-> Intervention -> Follow-up -> Learning points`, 'F59E0B');
  addFooter(s, 6);
}

// Slide 7: Editorial/letter/commentary
{
  const s = pptx.addSlide();
  addHeader(s, 'Editorial, Letter, Commentary, Perspective', 'Scholarly interpretation and debate formats');
  addCard(s, 0.6, 1.0, 3.0, 4.8, 'Editorial',
`Invited expert view\nFrames clinical significance\nUsually not original data`, COLORS.accent);

  addCard(s, 3.8, 1.0, 3.0, 4.8, 'Letter',
`Brief response to published work\nCritique, clarification, or reanalysis\nCan trigger post-publication review`, '14B8A6');

  addCard(s, 7.0, 1.0, 2.8, 4.8, 'Commentary',
`Focused interpretation of a topic\nDiscusses policy or practice implications`, 'F59E0B');

  addCard(s, 10.0, 1.0, 2.7, 4.8, 'Perspective',
`Argumentative expert viewpoint\nOften future-facing recommendations`, '8B5CF6');

  addCard(s, 0.6, 6.0, 12.1, 0.7, 'Note',
`These formats are valuable for context and critique but rank lower than controlled empirical studies for causal evidence.`, 'EF4444');
  addFooter(s, 7);
}

// Slide 8: Evidence hierarchy
{
  const s = pptx.addSlide();
  addHeader(s, 'Evidence Hierarchy Pyramid', 'From highest certainty to lowest');

  const levels = [
    { t: 'Systematic Review + Meta-analysis', c: '2563EB', w: 8.6 },
    { t: 'Randomized Controlled Trial', c: '1D4ED8', w: 7.5 },
    { t: 'Cohort Study', c: '0EA5E9', w: 6.4 },
    { t: 'Case-Control Study', c: '14B8A6', w: 5.3 },
    { t: 'Cross-Sectional Study', c: '22C55E', w: 4.2 },
    { t: 'Case Series / Case Report', c: 'F59E0B', w: 3.1 },
    { t: 'Editorial / Expert Opinion', c: 'EF4444', w: 2.0 }
  ];

  let y = 1.1;
  levels.forEach((lv, i) => {
    const x = (13.33 - lv.w) / 2;
    s.addShape(pptx.ShapeType.roundRect, {
      x, y, w: lv.w, h: 0.65,
      fill: { color: lv.c }, line: { color: lv.c }, rectRadius: 0.05
    });
    s.addText(lv.t, {
      x, y: y + 0.16, w: lv.w, h: 0.3,
      color: 'FFFFFF', bold: true, align: 'center', fontSize: 14
    });
    y += 0.72;
  });

  addFooter(s, 8);
}

// Slide 9: Reporting checklists and key metrics
{
  const s = pptx.addSlide();
  addHeader(s, 'Reporting Standards and Key Metrics', 'How quality and effect are communicated');
  addCard(s, 0.6, 1.0, 6.0, 2.9, 'Reporting Guidelines',
`CONSORT - randomized trials\nPRISMA - systematic reviews/meta-analyses\nSTROBE - observational studies\nCARE - case reports\nGRADE - certainty of evidence`, COLORS.accent);

  addCard(s, 6.8, 1.0, 5.9, 2.9, 'Common Statistics',
`OR: Odds Ratio\nRR: Relative Risk\nHR: Hazard Ratio\nCI: Confidence Interval\nI²: heterogeneity in meta-analysis`, '14B8A6');

  addCard(s, 0.6, 4.2, 12.1, 2.4, 'Quick Interpretation Rule',
`Strong publication quality = robust design + transparent reporting + appropriate statistics + reproducibility cues.`, '8B5CF6');
  addFooter(s, 9);
}

// Slide 10: Final comparison matrix
{
  const s = pptx.addSlide();
  addHeader(s, 'Comparison Matrix', 'Design, strength, and use case in one view');

  const headers = ['Type', 'Design', 'Evidence', 'Primary Use'];
  const rows = [
    ['Meta-analysis', 'Secondary (quantitative)', 'Very High', 'Pooled treatment effect'],
    ['Systematic Review', 'Secondary (structured)', 'Very High', 'Total evidence synthesis'],
    ['RCT', 'Experimental', 'High', 'Intervention efficacy'],
    ['Cohort', 'Observational', 'Moderate', 'Risk/prognosis'],
    ['Case-control', 'Observational', 'Moderate-Low', 'Rare disease associations'],
    ['Cross-sectional', 'Observational snapshot', 'Low-Moderate', 'Prevalence'],
    ['Case report/series', 'Descriptive', 'Low', 'Novel signal detection'],
    ['Editorial/Letter', 'Opinion/critique', 'Contextual', 'Debate and interpretation']
  ];

  s.addTable([headers, ...rows], {
    x: 0.6, y: 1.1, w: 12.1, h: 5.9,
    border: { type: 'solid', pt: 1, color: '2A3A63' },
    fill: '121A33',
    color: 'E6ECFF',
    fontFace: 'Calibri',
    fontSize: 11,
    rowH: 0.62,
    valign: 'middle',
    margin: 0.06,
    colW: [2.6, 3.1, 2.0, 4.4],
    autoFit: false,
    align: 'left',
    bold: false,
    cellProps: {
      0: { fill: '1F2D52', bold: true, color: 'FFFFFF', fontSize: 12 }
    }
  });

  addFooter(s, 10);
}

pptx.writeFile({ fileName: '/home/daytona/workspace/journal-articles-ppt/Journal_Article_Types_Detailed.pptx' });

Running Command

node "/home/daytona/workspace/journal-articles-ppt/make_ppt.js" && ls -la "/home/daytona/workspace/journal-articles-ppt/"

Journal Article Types Detailed

Presentation · PPTX

This is a shared conversation. Sign in to Orris to start your own chat.